About SURMOUNT-5 SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes
At our welcoming Colleyville medspa, we are committed to providing you with the knowledge and support you need to make informed decisions about your health
Now in 2024, in the week leading up to Halloween, we get the withdrawal of Prozac
Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
But the key difference with this weight-loss drug, besides the pesky matter of its legality, is that it appears to be much, much more powerful than those approved so far
[DOI] [PMC free article] [PubMed] [Google Scholar] [117].Milinovich GJ, Burrell PC, Pollitt CC, Klieve AV, Blackall LL, Ouwerkerk D, et al